Pearls for Menopause Management: I’m ready: now what?

Friday November 13, 2015

Susan Goldstein  MD  CCFP  FCFP  NCMP
Assistant Professor
Department of Family and Community Medicine
University of Toronto
Menopause: Straw + 10

<table>
<thead>
<tr>
<th>STAGES</th>
<th>-5</th>
<th>-4</th>
<th>-3b</th>
<th>-3a</th>
<th>-2</th>
<th>-1</th>
<th>+1a</th>
<th>+1b</th>
<th>+1c</th>
<th>+2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terminology</td>
<td>REPRODUCTIVE</td>
<td>MENOPAUSAL TRANSITION</td>
<td>POSTMENOPAUSE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration</td>
<td>Variable</td>
<td>Variable</td>
<td>1-3 yrs</td>
<td>2 yrs (1+1)</td>
<td>3-6 yrs</td>
<td>Remaining lifespan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PRINCIPAL CRITERIA

#### Menstrual cycle
- Variable to regular
- Regular
- Regular
- Subtle changes in flow length
- Variable length Persistent ≥7-day difference in length of consecutive cycles
- Interval of amenorrhea of ≥60 days

#### SUPPORTIVE CRITERIA

##### Endocrine
- FSH: Low
- AMH: Low
- Inhibin B: Low

##### Antral Follicle Count
- Low

#### DESCRIPTIVE CHARACTERISTICS

### Symptoms
- Vasomotor symptoms likely
- Vasomotor symptoms most likely
- Increasing symptoms of genitourinary syndrome of menopause (GSM)

---

* Blood draw on cycle days 2-5

** Approximate expected level based on assays using current international pituitary standard

↑ = elevated

Common Complaints During the Peri-menopause

- Hot flashes/night sweats
- Vag dryness/ dyspareunia/ lowered libido
- Urinary changes
- Sleep disturbance
- Depression, anxiety, tension/irritability
- Cognitive complaints
- Achy/stiff joints*
- Rapid HR/Palpitations
- Tingling hands & feet
- Hair thinning/loss
- Wt gain
Genitourinary Syndrome of Menopause (GSM)

**Definition**

- Collection of symptoms and signs associated with ↓ estrogen
- Involves changes to:
  - Labia majora/minora
  - Clitoris
  - Vestibule/introitus
  - Vagina
  - Urethra
  - Bladder

**Symptoms**

- Genital – dryness, burning, irritation
- Urinary – urgency, dysuria, recurrent UTIs
- Sexual – lack of lubrication, discomfort/pain, impaired function

*Adopted by the International Society for the Study of Women’s Sexual Health and NAMS; GSM: genitourinary syndrome of menopause; UTI: urinary tract infection.

An Update on the Menopause Guidelines for 2015: Key Guidelines

SOGC Guidelines: Managing Menopause (2014)

Global Consensus Statement on Menopausal Hormone Therapy. (2013)
More Guidelines

The 2013 British Menopause Society & Women’s Health Concern Recommendations On Hormone Replacement Therapy

http://min.sagepub.com/content/early/2013/05/23/1754045313489645.1.full


Recent Position Statements

NAMS: Statement on Continuing Use of Systemic Hormone Therapy After Age 65 (2015)

VMS
Non-hormonal treatments

SSRI/SNRI (OFF LABEL):
- Paroxetine CR, (approved in USA as Brisdelle 7.5 mg)
- Venlaxafine XR*
- Desvenlafaxine
- Citalopram*
- S-citalopram
- Fluoxetine

Gabapentinoids
- Gabapentin (OFF LABEL)
  - 300 mg qhs-900 mg (600qhs/300qam)
- Pregabalin
  - 150-300 mg

Clonidine
- .05 Mg BID : 4-6 week trial
**WHAT IS THE EVIDENCE FOR NON-HORMONAL TREATMENTS?**

NAMS 2015 Position Statement:  
Nonhormonal management of menopause-associated vasomotor symptoms  
*Menopause: Vol. 22, No. 11, 2015*

<table>
<thead>
<tr>
<th><strong>Recommended (good evidence)</strong></th>
<th><strong>Recommend with caution (may benefit, further studies req’d)</strong></th>
<th><strong>Not Recommended (negative, insufficient, or conflicting data)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRI/SNRI (I)</td>
<td>Weight loss (II)</td>
<td>Exercise/yoga (I)</td>
</tr>
<tr>
<td>Gabapentinoids (I-II)</td>
<td>Soy Isoflavone: S-equol derivatives (II)</td>
<td>Cooling techniques (V)</td>
</tr>
<tr>
<td>Clonidine (II)</td>
<td>Mindfulness based stress reduction (II)</td>
<td>Avoiding triggers (V)</td>
</tr>
<tr>
<td>CBT (I)</td>
<td>Stellate ganglion block (II)</td>
<td>Paced respiration (I)</td>
</tr>
<tr>
<td>Hypnosis (I)</td>
<td></td>
<td>OTC supps /herbals (I-II)</td>
</tr>
</tbody>
</table>

**Rationale:**  
Some interventions may have health benefits but may be unlikely to help VMS and will delay appropriate treatment
“Provided that the woman has been advised of the increase in risks associated with continuing HT beyond age 60 and has clinical supervision, extending HT use with the lowest effective dose is acceptable under some circumstances....

Use of HT should be individualized and not discontinued solely based on a woman’s age.”
### Absolute Benefits and Risks: HT Women Aged 50-59

<table>
<thead>
<tr>
<th>Condition</th>
<th>EPT</th>
<th>ET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hot flashes</td>
<td>-825</td>
<td>-900</td>
</tr>
<tr>
<td>Vulvovaginal atrophy</td>
<td>-875</td>
<td>-800</td>
</tr>
<tr>
<td>Fractures</td>
<td>-5</td>
<td>-6</td>
</tr>
<tr>
<td>Heart disease</td>
<td>-1</td>
<td>-4</td>
</tr>
<tr>
<td>Overall mortality</td>
<td>-6</td>
<td>-5</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>-1</td>
<td>??</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>+4</td>
<td>-7</td>
</tr>
<tr>
<td>Stroke</td>
<td>+1</td>
<td>+1</td>
</tr>
<tr>
<td>VTE</td>
<td>+6</td>
<td>+2</td>
</tr>
</tbody>
</table>

*Absolute numbers in women initiating HT at 50-59 years of age using HT for 5 years.
HT: hormone therapy; EPT: estrogen and progestogen therapy; ET: estrogen therapy; VTE: venous thromboembolism.

The Menopause Quick 6 Screen

**KEY Questions to help address menopausal symptoms:**

1. Any changes in your periods?
2. Are you having any hot flashes?
3. Any vaginal dryness or pain or sexual concerns?
4. Any bladder issues/ incontinence?
5. How’s your sleep?
6. How’s your mood?

Contraindications to Hormone Therapy

Contraindications to HT

- Unexplained vag bleed
- Known or suspected Br CA
- Acute liver dx
- Acute CVS dx
- Recent CVA
- Active thromboembolic dx
- Pregnancy
- Migraine with aura
The MenoPro app is designed to help women work with their healthcare providers to personalize the management of their menopausal symptoms and to choose the optimal treatment.

ORAL HT Formulations In Canada

| E only*         | CEE (Premarin)  |
|                | E2 (Estrace)   |
|                | EE (Estragyn)  |
| P only         | MP (Prometrium)|
|                | MPA (Provera)  |
|                | NETA (Norlute) |
| E + P combo products | CEE + MPA (Premplus) |
|                | E2 + NETA (Activelle, Activelle LD) |
|                | E2 + DRSP (Angelique) |

*No progestogen required in hysterectomized women.

HT: hormone therapy; CEE: conjugated equine estrogens; E2: estradiol; EE: esterified estrogens; MP: micronized progesterone; MPA: medroxyprogesterone acetate; NETA: norethindrone acetate; DRSP: drospirenone.
### TRANSDERMAL HT Formulations Available In Canada

<table>
<thead>
<tr>
<th>E only*</th>
<th>E + P combo products</th>
</tr>
</thead>
</table>
| • E2 patch (Climara, Estraderm, Estradot, Oesclim)  
• E2 gel (Divigel, Estrogel) | • E2 + LNG patch (Climara Pro)  
• E2 + NETA patch (Estalis)  
• E2 gel 0.06% + MP (Estrogel ProPak) |

*No progestogen required in hysterectomized women.
HT: hormone therapy; E2: estradiol; NETA: norethindrone acetate; LNG: levonorgestrel.
INITIATING HORMONE THERAPY OPTIONS:
Available Products

1. Chart of available products from SOGC
   www.sogc.org

2. Chart of available products from NAMS
   http://www.menopause.org/docs/professional/htcharts.pdf?sfvrsn=6
What to say to patients
(50’s/within 10 yrs of menopause)

RISKS

• Heart disease-no increased risk, potential protection, yet unproven
• No significant increase in CVA
• VTE: occurs rarely even in first 1-2 yrs
• Potential breast cancer risk after 5 years
  • Will optimize rx regimen & will monitor & revisit yearly
• Appears to be brain neutral
• Oral E may worsen stress incontinence
• Increased risk of gallstones (oral E)

BENEFITS

• Symptom relief:
  ➢ VMS, GSM,
• Prevention of osteoporosis and related fractures
• May benefit mood, sleep, joint pain, OAB and recurrent UTIs
• May reduce risk DM
• Unpredictable effect on sexual function/libido
• There is no absolute timeline-individualization is key
Patient Resources

- SIGMA Canadian Menopause Society [www.sigmamenopause.com](http://www.sigmamenopause.com)

- Society of Obstetricians and Gynecologists of Canada (SOGC) [www.sogc.org](http://www.sogc.org) and [menopauseandu.ca](http://menopauseandu.ca)

- North American Menopause Society (NAMS) [www.menopause.org](http://www.menopause.org) : Menopro-app!
"Having nine lives is cool, but if I have to go through menopause again, forget it!"

THANK YOU!

susan.goldstein@utoronto.ca